Experts have warned that blockbuster weight loss drugs like Ozempic and Mounjaro may increase the risk of depression and suicidal thoughts. A study by international researchers found that these medicines could disrupt levels of dopamine, a mood-regulating chemical in the brain. The European Medicines Agency is launching a review of these drugs following reports of adverse psychiatric events. The study's authors are urging caution and genetic testing to better protect individuals at high risk of developing depression while taking these drugs.